Comparing the current results to its competitors, Collegium Pharmaceutical Inc reported Revenue increase in the 2 quarter 2026 by 6.67 % year on year. The sales growth was above Collegium Pharmaceutical Inc 's competitors' average revenue growth of 2.88 %, achieved in the same quarter.
Collegium Pharmaceutical Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, facing competition primarily from generic opioid and stimulant markets, including both long-acting/extended-release and immediate-release drugs. It also competes with non-opioid alternative drugs developed by other pharmaceutical and biotechnology companies. Vertex Pharmaceuticals Incorporated is a noted competitor, having received approval in January 2025 for suzetrigine to treat moderate to severe acute pain in adults. The company's products Belbuca, Xtampza ER, and the Nucynta Products compete with oral opioids, transdermal opioids, local anesthetic patches, and implantable and external infusion pumps. Jornay PM competes with branded and generic methylphenidate products for ADHD treatment. Competitors generally have greater financial and other resources. Key competitive factors include therapeutic efficacy, convenience of dosing and distribution, abuse deterrence (specifically for Xtampza ER), safety, and cost.
With revenue growth of 6.67 % within Overall company, Collegium Pharmaceutical Inc achieved improvement in market share, within Overall company to approximately 0.81 %. << More on COLL Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Collegium Pharmaceutical Inc
Viatris Inc Share Performance
+29.65%
This Year
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Ensysce Biosciences Inc is a biopharmaceutical company that operates on a business model centered around developing and commercializing novel therapies using their proprietary drug delivery technology, known as MedXPRESS™. This technology allows for precise control of drug release and enhanced delivery to target tissues, with a focus on improving therapeutic outcomes and patient compliance.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
Sources:
Collegium Pharmaceutical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Collegium Pharmaceutical Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
